Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy
OPEN The Journal of allergy and clinical immunology | 4 Jul 2016
M Frick, J Fischer, A Helbling, F Ruëff, D Wieczorek, M Ollert, W Pfützner, S Müller, J Huss-Marp, B Dorn, T Biedermann, J Lidholm, G Ruecker, F Bantleon, M Miehe, E Spillner and T Jakob
Component resolution recently identified distinct sensitization profiles in honey bee venom (HBV) allergy, some of which were dominated by specific IgE to Api m 3 and/or Api m 10, which have been reported to be underrepresented in therapeutic HBV preparations.
* Data courtesy of Altmetric.com